New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.

about

New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q39007500

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

New systemic strategies for ov ...... in non-small cell lung cancer.

@en

New systemic strategies for ov ...... in non-small cell lung cancer.

@nl

type

Item

label

New systemic strategies for ov ...... in non-small cell lung cancer.

@en

New systemic strategies for ov ...... in non-small cell lung cancer.

@nl

prefLabel

New systemic strategies for ov ...... in non-small cell lung cancer.

@en

New systemic strategies for ov ...... in non-small cell lung cancer.

@nl

P1476

New systemic strategies for ov ...... in non-small cell lung cancer

@en

P2093

Erika Rijavec

http://www.w3.org/2001/XMLSchema#string

Federica Biello

http://www.w3.org/2001/XMLSchema#string

Giulia Barletta

http://www.w3.org/2001/XMLSchema#string

Simona Coco

http://www.w3.org/2001/XMLSchema#string

P2860

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

P304

19-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2016.1261109

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27841028

http://www.w3.org/2001/XMLSchema#string